In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015, Aurobindo Pharma has informed that Aurogen South Africa (Pty), (Aurogen) a wholly owned step-down subsidiary of the Company in South Africa, has entered into an agreement with Rene Glyne Family trust to sell and dispose of the entire 24.5% shares held by Aurogen. After the disposal of 24.5% shares held by Aurogen, Aurogen will cease to be the joint venture partner of Novagen BBBEE Invest Co (Proprietary). The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July 2023, is enclosed as ‘Annexure’.
The above information is a part of company’s filings submitted to BSE.
